Trump announces trade deal with EU following months of negotiations
Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported first quarter EPS of $1.80, $0.28 better than the analyst estimate of $1.52. Revenue for the quarter came in at $11.2B versus the consensus estimate of $10.68B.
Guidance
Bristol-Myers Squibb sees FY 2025 EPS of $6.70-$7.00 versus the analyst consensus of $6.74.
Bristol-Myers Squibb sees FY 2025 revenue of $45.80B-$46.80B versus the analyst consensus of $45.76B.
Bristol-Myers Squibb’s stock price closed at $48.53. It is down -18.67% in the last 3 months and up 8.57% in the last 12 months.
Bristol-Myers Squibb saw 1 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb’s stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb’s Financial Health score is "good performance".
Check out Bristol-Myers Squibb’s recent earnings performance, and Bristol-Myers Squibb’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar